H.R. 5160 · 119th Congress · Health
Stem Cell Therapeutic and Research Reauthorization Act of 2025
Reauthorizes bone marrow and cord blood transplant programs through fiscal year 2031. AI-read
- IntroducedSep 4, 2025 Done
- CommitteeReported Jul 2, 2026 Done
- House floorPassed by voice vote · Jul 20, 2026 Done
- Senate floorAwaiting vote Current stage
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).
The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research.
Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
Congressional Research Service · summary of “Reported to House” version · Jul 2, 2026
Who lobbies on it
1 organization · 1 filing · Q3 2025–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
American Benefits Council
1 of 5 quarters
“…HR 5160 / S. 2403”
$830K lobbying spend in 2026 to date, all issuesQ1 2026 filing
Organizations that named H.R. 5160 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
16 actions · newest first- Jul 21, 2026Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
- Jul 20, 2026Motion to reconsider laid on the table Agreed to without objection.
- Jul 20, 2026On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
- Jul 20, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
Show all 16 actionsShow fewer
- Jul 20, 2026DEBATE - The House proceeded with forty minutes of debate on H.R. 5160.
- Jul 20, 2026Considered under suspension of the rules. (consideration: CR H4642-4643)
- Jul 20, 2026Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
- Jul 2, 2026Placed on the Union Calendar, Calendar No. 629.
- Jul 2, 2026Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
- May 21, 2026Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
- May 21, 2026Committee Consideration and Mark-up Session Held
- May 13, 2026Forwarded by Subcommittee to Full Committee by Voice Vote.
- May 13, 2026Subcommittee Consideration and Mark-up Session Held
- Sep 4, 2025Referred to the Subcommittee on Health.
- Sep 4, 2025Referred to the House Committee on Energy and Commerce.
- Sep 4, 2025Introduced in House
What members said about it
-
Today, the U.S. House of Representatives overwhelmingly approved Rep. Chris Smith (R-NJ)’s legislation to authorize more than $280 million over five years for two collaborative programs that provide lifesaving treatments and therapies…
“The bill before us today authorizes $280 million for these programs over 5 years—$115 million for cord blood and $165 million for the bone marrow program—to ensure that thousands of present and future patients benefit from this exciting field of regenerative medicine.”
-
Key Committee Advances Reed’s Bill to Renew & Improve National Bone Marrow & Cord Blood Programs
In a big step toward enhancing patient access to life-saving bone marrow and cord blood transplants, the Senate Committee on Health, Education, Labor and Pensions (HELP) today unanimously voted to advance U.S Senator Jack Reed’s (D-RI)…
“Thanks to sustained federal investment, advancements in innovative research have been amazing and we want to accelerate that progress by passing this bill and funding these life-saving programs. This bill will help patients and families in their time of need as they face unimaginable circumstances. It provides direct…”
-
During their full committee markup today, the House Committee on Energy and Commerce unanimously approved two critical public health reauthorization bills authored by Rep. Chris Smith (R-NJ)—HR 4348, the Kay Hagan Tick Act, and HR 5160, the…
“Now that these critical, life-enhancing bills have passed out of the Energy & Commerce Committee, we are one step closer to getting them across the finish line and onto President Trump’s desk for his signature.”
-
Two critical public health reauthorization bills authored by Rep. Chris Smith (R-NJ)—HR 5160, the Stem Cell Therapeutic and Research Reauthorization Act of 2025, and HR 4348, the Kay Hagan Tick Act—today passed out of the House Committee on…
“I am grateful to the Subcommittee on Health, especially Chairman Morgan Griffith (R-VA), for advancing these critical, life-enhancing bills to assist the millions of Americans suffering from chronic health conditions.”
-
Rep. Chris Smith (R-NJ), Co-Chair of the Congressional Pro-Life Caucus, Sen. Roger Wicker (R-MS), and 21 other Republican members of Congress sent a letter to National Institutes of Health (NIH) Director Dr. Jay Bhattacharya, urging him to…
“The NIH should never have allowed research that relies upon and incentivizes the destruction of human life to be funded with billions of taxpayer dollars. It certainly should refrain from continuing to do so, especially after that great expense has delivered so little benefit for patients.”
-
Scott, Reed, Smith, and Lankford offer bill to reauthorize and strengthen the National Marrow Donor Program and the National Cord Blood Inventory.
“For patients and families facing life-threatening diseases like sickle cell anemia, bone marrow and cord blood transplants can offer a cure and a second chance at life. The Stem Cell Therapeutic and Research Reauthorization Act of 2026 ensures that these life-saving programs continue to connect patients with donors…”
-
Bipartisan Reed-Scott Bill Offers Hope for Life-Saving Research & Life-Enhancing Treatments and Care
In an effort to help thousands of patients suffering from diseases requiring bone marrow and cord blood transplants, U.S Senator Jack Reed (D-RI) today introduced the Stem Cell Therapeutic and Research Reauthorization Act of 2026 (S.4109).
“Ultimately, this is all about helping patients and families in their time of need as they face unimaginable circumstances. It provides direct support to these critical institutions that do incredible research, match donors and patients, help save live lives, and improve health outcomes.”
-
At a news conference today hosted by Rep. Chris Smith (R-NJ), a panel of doctors and lawmakers launched the bipartisan Stem Cell Therapeutic and Research Reauthorization Act of 2025 (HR 5160) and discussed its positive impacts on research,…
“We have introduced new legislation, HR 5160, which reauthorizes the Stem Cell Therapeutic and Research Act of 2005—a law which I sponsored more than two decades ago.”
-
Bipartisan Bill Introduced to Reauthorize National Cord Blood and Bone Marrow Transplant Programs
A bipartisan group of lawmakers introduced legislation in the U.S. House of Representatives today to reauthorize more than $280 million over five years for national cord blood and bone marrow transplant programs—critical initiatives that…
“These programs represent our nation’s unwavering commitment to advancing life-saving medical research and providing hope to millions of Americans battling chronic and life-threatening illnesses.”
-
New legislation to authorize more than $280 million over five years for national cord blood and bone marrow transplant programs was introduced in the House of Representatives Thursday with significant bipartisan support, building momentum…
“Breathtaking scientific advancements have turned medical waste—post-birth placentas and umbilical cord blood—into medical miracles that cure and treat more than 75 diseases, including leukemia, lymphoma and sickle cell anemia.”